UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2534-2543

2005

Volltextzugriff (PDF)

Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5958-5964

2009

Volltextzugriff (PDF)

Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease

The Journal of infectious diseases, 2000-08, Vol.182 (2), p.428-434

2000

Volltextzugriff (PDF)

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

The New England journal of medicine, 2004-06, Vol.350 (23), p.2335-2342

2004

Volltextzugriff (PDF)

Reply to S.N. Wolff

Journal of clinical oncology, 2010-07, Vol.28 (19), p.e324-e324

2010

Volltextzugriff (PDF)

Analysis of tumor burden versus progression-free survival for Phase II decision making

Contemporary clinical trials, 2011-05, Vol.32 (3), p.446-452

2011

Volltextzugriff (PDF)

Targeted therapy: wave of the future

Journal of clinical oncology, 2005-03, Vol.23 (8), p.1776-1781

2005

Volltextzugriff (PDF)

Data Submission Standards and Evidence Requirements

The oncologist (Dayton, Ohio), 2010-05, Vol.15 (5), p.488-491

2010

Volltextzugriff (PDF)

Recommended changes to oncology clinical trial design: Revolution or evolution?

European journal of cancer (1990), 2008-01, Vol.44 (1), p.8-11

2008

Volltextzugriff (PDF)

Targeted therapy : Wave of the future: Breast cancer

Journal of clinical oncology, 2005, Vol.23 (8), p.1776-1781

2005

Volltextzugriff (PDF)

Endpoints and other considerations in phase I studies of targeted anticancer therapy : Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Commentary

European journal of cancer (1990), 2008, Vol.44 (1)

2008

Volltextzugriff (PDF)

Design and conduct of phase II studies of targeted anticancer therapy : Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Commentary

European journal of cancer (1990), 2008, Vol.44 (1)

2008

Volltextzugriff (PDF)

Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity

Blood, 1995-11, Vol.86 (9), p.3287-3294

1995

Volltextzugriff (PDF)

Recombinant human thrombopoietin clinical development

Stem cells (Dayton, Ohio), 1998-05, Vol.16 (S1), p.199-206

1998

Volltextzugriff (PDF)

Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

Cancer, 1993-11, Vol.72 (9), p.2656-2659

1993

Volltextzugriff (PDF)

Polyethylene glycol conjugated interleukin-2 : clinical and immunologic effects in patients with advanced renal cell carcinoma

Investigational new drugs, 1993-06, Vol.11 (2-3), p.211-217

1993

Volltextzugriff (PDF)

Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma

Journal of immunotherapy (1997), 1994-10, Vol.16 (3), p.224-228

1994

Volltextzugriff (PDF)

Effects of cytochalasins B and D on alloxan inhibition of insulin release

Biochemical and biophysical research communications, 1975-10, Vol.66 (4), p.1089-1096

1975

Volltextzugriff (PDF)

Management of Pregnancy-Associated Thrombotic Thrombocytopenia Purpura

American journal of perinatology reports, 2013-05, Vol.3 (1), p.045-050

2013

Volltextzugriff (PDF)

Management of pregnancy-associated thrombotic thrombocytopenia purpura

AJP reports, 2013, Vol.3 (1), p.45-50

2013

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)
Berichte
(1)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Female
(11)
Male
(9)
Adult
(8)
Middle Aged
(8)
Oncology
(8)
Pharmacology. Drug Treatments
(6)
Tumors
(6)
Aged
(5)
Antineoplastic Agents
(4)
Immunotherapy
(4)
Interleukin-2 - Therapeutic Use
(4)
Recombinant Proteins - Adverse Effects
(4)
Antibodies, Monoclonal, Humanized
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Disease-Free Survival
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials

Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Reply to S.N. Wolff

Analysis of tumor burden versus progression-free survival for Phase II decision making

Targeted therapy: wave of the future

Data Submission Standards and Evidence Requirements

Recommended changes to oncology clinical trial design: Revolution or evolution?

Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy

Targeted therapy : Wave of the future: Breast cancer

Endpoints and other considerations in phase I studies of targeted anticancer therapy : Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Commentary

Design and conduct of phase II studies of targeted anticancer therapy : Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Commentary

Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity

Recombinant human thrombopoietin clinical development

Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy

Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

Polyethylene glycol conjugated interleukin-2 : clinical and immunologic effects in patients with advanced renal cell carcinoma

Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma

Effects of cytochalasins B and D on alloxan inhibition of insulin release

Management of Pregnancy-Associated Thrombotic Thrombocytopenia Purpura

Management of pregnancy-associated thrombotic thrombocytopenia purpura

Suchergebnisse filtern